Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2

被引:190
|
作者
Lam, XM [1 ]
Yang, JY [1 ]
Cleland, JL [1 ]
机构
[1] Genentech Inc, Dept Pharmaceut Res & Dev, S San Francisco, CA 94080 USA
关键词
D O I
10.1021/js970143s
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Recombinant humanized monoclonal antibody HER2, rhuMAb HER2, in liquid formulations undergoes oxidation when exposed to intense light and elevated temperatures (30 & 40 degrees C). Met-255 in the heavy chain of the Fe region of the antibody is the primary site of oxidation. Met-431 of the Fe fragment can also be oxidized under extreme conditions. The amount of oxidation was determined by cleaving the Fab and Fe fragments by papain digestion, and the oxidized Fe fragment was detected by hydrophobic interaction chromatography, Oxidation of rhuMAb HER2 was also formulation dependent, The presence of NaCl in the rhuMAb HER2 formulation caused an increase in oxidation at higher temperatures after contact with stainless steel containers or stainless steel components in the filling process. The corrosion of stainless steel by chloride ions at the low pH of the formulation buffer generated iron ions that catalyzed methionine oxidation in rhuMAb HER2, Temperature-induced oxidation of rhuMAb HER2 occurred by the formation of free radicals, and light-induced oxidation of rhuMAb HER2 occurred via singlet oxygen pathway, Antioxidants, such as methionine, sodium thiosulfate, catalase, or platinum, prevented Met oxidation in rhuMAb HER2, presumably as free radicals or oxygen scavengers. The minimum effective levels (molar ratios of protein to antioxidant) required to inhibit temperature induced oxidation were 1:5 and 1:25 for methionine and thiosulfate, respectively. A thiosulfate adduct of rhuMAb HER2 was observed by cation-exchange chromatography. These studies demonstrate that stoichiometric amounts of methionine and thiosulfate are sufficient to eliminate temperature-induced oxidation of rhuMAb HER2 caused by free radicals that were generated by the presence of metal ions and peroxide impurities in the formulation.
引用
收藏
页码:1250 / 1255
页数:6
相关论文
共 50 条
  • [21] Increased CD4 T Cell and Antibody Responses by Addition of Recombinant HER2 Protein to MVA-BN®-HER2
    Mandl, Stefanie J.
    Rountree, Ryan B.
    Cote, Joseph
    dela Cruz, Tracy
    Giffon, Thierry
    Lombardo, John R.
    Trent, Erica
    Laus, Reiner
    Delcayre, Alain
    JOURNAL OF IMMUNOTHERAPY, 2012, 35 (09) : 772 - 772
  • [22] HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma
    Purdie, Colin A.
    Jordan, Lee B.
    McCullough, Jean B.
    Edwards, Sharon L.
    Cunningham, Joan
    Walsh, Miriam
    Grant, Andrew
    Pratt, Norman
    Thompson, Alastair M.
    HISTOPATHOLOGY, 2010, 56 (06) : 702 - 707
  • [23] Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy
    Pegram, M
    Slamon, D
    SEMINARS IN ONCOLOGY, 2000, 27 (05) : 13 - 19
  • [24] Assessment of a new Anti-HER2 monoclonal antibody, SV2-61γ:: A best concordance with HER2 FISH
    Kitano, Yuriko
    Umemura, Shinobu
    Ohbayashi, Hirokazu
    Takenaga, Masato
    Osamura, Robert Yoshiyuki
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2007, 15 (04): : 389 - 393
  • [25] Monoclonal-Antibody-Templated Gold Nanoclusters for HER2 Receptors Targeted Fluorescence Imaging
    Zhang, Xin
    Chen, Muhua
    Zhang, Yunwei
    Hou, Yi
    Wu, Yue
    Yao, Meinan
    Li, Liqiang
    Shi, Linqing
    Liu, Tianyu
    Hu, Biao
    Zhao, Huiyun
    Li, Xiaoda
    Shi, Jiyun
    Jia, Bing
    Wang, Fan
    ACS APPLIED BIO MATERIALS, 2020, 3 (10) : 7061 - 7066
  • [26] Monoclonal Antibodies, Small Molecule Inhibitors and Antibody-drug Conjugates as HER2 Inhibitors
    Li, Xiu-Fang
    Liu, Chen-Fu
    Rao, Guo-Wu
    CURRENT MEDICINAL CHEMISTRY, 2021, 28 (17) : 3339 - 3360
  • [27] Development of a highly specific HER2 monoclonal antibody for immunohistochemistry using protein microarray chips
    Qi, Lili
    Zhou, Lixin
    Lu, Mingmin
    Yuan, Kehu
    Li, Zhongwu
    Wu, Guiyin
    Huang, Xiaozheng
    Shen, Yi
    Zhao, Min
    Fu, Wei
    Chu, Boyang
    Wang, Guangli
    Ren, Fangfang
    Ma, Donghui
    Chen, Jian
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 484 (02) : 248 - 254
  • [28] Preclinical antitumor activity of an Fc domain-optimized HER2 monoclonal antibody (mAb)
    Nordstrom, J. L.
    Huang, L.
    Yang, Y.
    Tuaillon, N.
    Stavenhagen, J. B.
    Stewart, S.
    Moore, P. A.
    Johnson, S.
    Koenig, S.
    Bonvini, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance
    Pedersen, Mikkel W.
    Jacobsen, Helle J.
    Koefoed, Klaus
    Dahlman, Anna
    Kjaer, Ida
    Poulsen, Thomas T.
    Meijer, Per-Johan
    Nielsen, Lars S.
    Horak, Ivan D.
    Lantto, Johan
    Kragh, Michael
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (03) : 669 - 680
  • [30] Pathological evaluation of HER2 overexpression: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab)
    Umemura, S
    Sekido, Y
    Itoh, H
    Osamura, RY
    ACTA HISTOCHEMICA ET CYTOCHEMICA, 2002, 35 (02) : 77 - 81